Esm1-flox Mouse
一般名
Esm1-flox
製品ID
S-CKO-15131
背景情報
C57BL/6JCya
系統ID
CKOCMP-71690-Esm1-B6J-VA
状況
このマウス系統を論文で使用する場合は、「Esm1-flox Mouse（カタログ番号S-CKO-15131）はサイアジェンから購入しました。」と引用してください。
製品タイプ
年齢
遺伝子型
性別
数量
標準的な配送方法では、少なくとも3匹のヘテロ接合体キャリアを保証しています。ホモ接合体キャリアや指定された性別の個体の繁殖サービスも利用可能です。
基本情報
系統名
Esm1-flox
系統ID
CKOCMP-71690-Esm1-B6J-VA
遺伝子名
製品ID
S-CKO-15131
遺伝子別名
ESM-1, 0610042H23Rik
遺伝子別名
C57BL/6JCya
NCBI ID
修正
Conditional knockout
染色体
Chr 13
表現型
アプリケーション
--
さらに
系統詳細
EnsemblトランスクリプトID
ENSMUST00000038144
NCBIトランスクリプトID
NM_023612
ターゲット領域
Exon 1
有効領域の大きさ
~2.8 kb
遺伝子研究の概要
Esm1, also known as endocan, is a secreted protein. It has been implicated in promoting proliferation, angiogenesis, and other oncogenic processes in multiple cancers [1-10]. It is associated with various signaling pathways, such as the Akt pathway, which it activates to drive cancer-related biological functions [1, 4-7].
In ovarian cancer, Esm1 knockdown inhibited cell proliferation, apoptosis escape, the cell cycle, angiogenesis, migration, and invasion. Hypoxia-induced Esm1 upregulation promoted the Warburg effect and vasculogenic mimicry through the PKM2-dependent mechanism [1,2].
In gastric cancer, Esm1 promoted angiogenesis and peritoneal metastasis by binding to c-Met and activating the MAPK/ERK pathway, and also triggered epithelial-to-mesenchymal transition via the EGFR/HER3-Akt/ANGPT2 pathway [3,4].
In colorectal cancer, Esm1 promoted angiogenesis by activating the PI3K/Akt/mTOR pathway [5].
In triple-negative breast cancer, Esm1 promoted cell proliferation through the AKT/NF-κB/Cyclin D1 pathway [6].
In esophageal squamous cell carcinoma, silencing Esm1 suppressed cell proliferation, migration, and invasion [7].
In cervical squamous cell carcinoma, Esm1 overexpression promoted carcinoma angiogenesis and tumor progression through the VEGF/ERK signaling pathway [8].
In conclusion, Esm1 is a crucial factor in promoting cancer-related processes in multiple cancer types, including ovarian, gastric, colorectal, triple-negative breast, esophageal squamous cell, and cervical squamous cell carcinomas. The study of Esm1 using gene knockdown and other functional studies in these cancer models has revealed its significant role in cancer development, progression, and angiogenesis, suggesting it could be a potential therapeutic target and prognostic biomarker for these diseases.
References：
1. Li, Yu-Kun, Zeng, Tian, Guan, Yang, Zhang, Qun-Feng, Zou, Juan. 2023. Validation of ESM1 Related to Ovarian Cancer and the Biological Function and Prognostic Significance. In International journal of biological sciences, 19, 258-280. doi:10.7150/ijbs.66839. https://pubmed.ncbi.nlm.nih.gov/36594088/
2. Zhang, Juan, Ouyang, Fan, Gao, Anbo, Long, Yunzhu, Li, Yukun. 2024. ESM1 enhances fatty acid synthesis and vascular mimicry in ovarian cancer by utilizing the PKM2-dependent warburg effect within the hypoxic tumor microenvironment. In Molecular cancer, 23, 94. doi:10.1186/s12943-024-02009-8. https://pubmed.ncbi.nlm.nih.gov/38720298/
3. Yang, Jiaoyang, Shu, Gege, Chen, Tao, Li, Dongbao, Zhou, Jin. 2023. ESM1 Interacts with c-Met to Promote Gastric Cancer Peritoneal Metastasis by Inducing Angiogenesis. In Cancers, 16, . doi:10.3390/cancers16010194. https://pubmed.ncbi.nlm.nih.gov/38201620/
4. Yang, Yi-Chieh, Ho, Ko-Hao, Pan, Ke-Fan, Lee, Wei-Jiunn, Chien, Ming-Hsien. 2024. ESM1 facilitates the EGFR/HER3-triggered epithelial-to-mesenchymal transition and progression of gastric cancer via modulating interplay between Akt and angiopoietin-2 signaling. In International journal of biological sciences, 20, 4819-4837. doi:10.7150/ijbs.100276. https://pubmed.ncbi.nlm.nih.gov/39309430/
5. Yang, Liqun, Dong, Zhigang, Li, Shuyu, Chen, Tieliang. 2023. ESM1 promotes angiogenesis in colorectal cancer by activating PI3K/Akt/mTOR pathway, thus accelerating tumor progression. In Aging, 15, 2920-2936. doi:10.18632/aging.204559. https://pubmed.ncbi.nlm.nih.gov/37100467/
6. Liu, Wentong, Yang, Yang, He, Bincan, Zhang, Min, Dong, Zhiqiang. . ESM1 promotes triple-negative breast cancer cell proliferation through activating AKT/NF-κB/Cyclin D1 pathway. In Annals of translational medicine, 9, 533. doi:10.21037/atm-20-7005. https://pubmed.ncbi.nlm.nih.gov/33987231/
7. Li, Juan, Yang, Dong, Zhang, Cong, Dai, Suli, Shan, Baoen. 2022. ESM1 Is a Promising Therapeutic Target and Prognostic Indicator for Esophageal Carcinogenesis/Esophageal Squamous Cell Carcinoma. In BioMed research international, 2022, 5328192. doi:10.1155/2022/5328192. https://pubmed.ncbi.nlm.nih.gov/35937390/
8. Li, Dan, Su, Xiaomin, Xue, Shen, Tang, Xianbing, Huang, Yugang. 2023. Targeting ESM1/ VEGFα signaling axis: a promising therapeutic avenue for angiogenesis in cervical squamous cell carcinoma. In Journal of Cancer, 14, 1725-1735. doi:10.7150/jca.84654. https://pubmed.ncbi.nlm.nih.gov/37476182/
品質管理基準
精子検査
凍結前の精子濃度を測定し、精子の生存能力の判定します。
凍結後の精子では、各バッチから1本の凍結保存された精子を選び出し、体外受精に使用します。
環境基準:
SPF対応地域:
グローバル由来:
Cyagenお問い合わせ
カスタムの動物モデルに関するご相談は、下記のフォームにご記入いただき、ご連絡いただくか見積もりをご依頼ください。
Cyagenはお客様のプライバシーを大変重視しています。当社の最新の製品や情報をお届けしたいと思っています。お客様の設定をご確認ください。
これらの配信はいつでも解除できます。配信停止方法およびデータ保護の詳細は プライバシーポリシー をご確認ください。
以下のボタンをクリックすることで、このフォームにご入力いただいた個人情報をCyagenが保存・処理し、ご要望のコンテンツを提供することに同意されたことになります。